Previous 10 | Next 10 |
NetworkNewsWire Editorial Coverage : Diagnostic devices are a crucial part of the medical technology sector, and many companies are pressing forward with work in this area. Zenosense, Inc. (OTC: ZENO) ( ZENO Profile ) has just announced breakthrough quantitative test results for its MIDS Ca...
Palm Beach, FL – (June 19, 2018) – The healthcare solutions sector of the overarching biotech industry is an active market as of late, with leaders in the space unveiling new breakthroughs, therapies and products designed to meet a variety of healthcare patient needs and conditions...
VALENCIA, SPAIN., June 19, 2018 (GLOBE NEWSWIRE) -- Zenosense, Inc. (OTC PINK: ZENO) ("Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the...
VALENCIA, SPAIN, May 24, 2018 (GLOBE NEWSWIRE) -- Zenosense, Inc. (OTC PINK: ZENO) ("Zenosense", the "Company"), a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care handheld device for the early detection of cer...
Healthcare technology company Zenosense (OTC: ZENO), through its joint venture ownership of MIDS Medical Limited (“MML”), is developing MIDS Cardiac™ to give first responders a rapid, highly sensitive analysis of heart biomarkers. An article discussing the company reads: &...
Every 43 seconds, someone in the U.S. has a heart attack Over six million patients visit U.S. emergency rooms reporting chest pain each year Chest pain symptoms can be hard to diagnose in emergencies but are vital to assessing for heart attack Zenosense’s handheld device aims t...
Healthcare technology company Zenosense (OTC: ZENO) is well positioned to capitalize on the projected growth in the global point-of-care (“POC”) diagnostics market, forecast to grow at a CAGR of 10 percent, from $23.71 billion in 2017 to $38.13 billion in 2022 according to a rece...
Global Point Of Care (POC) diagnostics market projected to grow from $23.71 billion in 2017 to $38.13 billion in 2022 Patented diagnostic technology for POC devices Initial development of MIDS Cardiac™, a POC device for early and rapid cardiac biomarker detection Global cardiac...
Healthcare technology company Zenosense (OTC: ZENO) is primarily focused on the development and commercialization of MIDS Cardiac™ through the company’s joint venture ownership in MIDS Medical Limited (“MML”). An article discussing the company reads: “True, h...
Global biomarker diagnostic testing market projected to reach $53.34 billion by 2021 from $27.95 billion in 2016 Zenosense’s device development incorporates key technology which is patent protected Technology platform could be used to test for a wide variety of common medical con...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK , June 5, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective OTCQX® and OTCQB® markets and Caveat Emptor Desig...
VALENCIA, SPAIN, March 20, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection o...
Agreement signed with third party investor to fund up to $1.2 million to support next crucial development phase of MIDS Cardiac POC diagnostic device Patented MIDS technology has successfully detected commercial assay beads at a level approximately four times better than the threshold adv...